Targacept, Inc.
Ronald Heemstra is an experienced medicinal chemist currently serving as Scientist III at Targacept, Inc. since June 2007, specializing in medicinal chemistry with a focus on environmental safety. Prior to this role, Ronald held positions at Pfizer from 2001 to 2007, where responsibilities included serving as Sr. Associate Scientist in Discovery Chemistry within the CVMED division and as Assistant Scientist in Chemical Process Development. Ronald earned a Bachelor of Science degree in Chemistry and Engineering Science from Hope College, completing the program in 2001.
This person is not in any teams
Targacept, Inc.
Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.